Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
$225.02 Million in Sales Expected for Alkermes Plc (NASDAQ:ALKS) This Quarter
08:30am, Monday, 27'th Apr 2020
Equities analysts expect Alkermes Plc (NASDAQ:ALKS) to post $225.02 million in sales for the current quarter, Zacks reports. Six analysts have provided estimates for Alkermes’ earnings, with the low
The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight
08:37pm, Sunday, 26'th Apr 2020
The week ended April 24 turned out to be an up-and-down one for biotech stocks, as the sector swayed along with the broader market. Two FDA approvals came through this week,...
Alkermes (NASDAQ:ALKS) Lifted to "Hold" at BidaskClub
06:32am, Saturday, 25'th Apr 2020
BidaskClub upgraded shares of Alkermes (NASDAQ:ALKS) from a sell rating to a hold rating in a report issued on Tuesday morning, BidAskClub reports. Other research analysts also recently issued reports
Pune, April 24, 2020 -- The global opioid use disorder market size is projected to reach USD 4.50 billion by 2026, exhibiting a CAGR of 10.8% during the forecast period..
20 Healthcare Stocks Moving In Thursday's Pre-Market Session
11:31am, Thursday, 23'rd Apr 2020
Gainers
• Immunomedics, Inc. (NASDAQ:IMMU) stock rose 31.29% to $28.87 during Thursday's pre-market session. The most recent rating by H.C. Wainwright, on Apr 23, is at...
Alkermes to Host Conference Call to Discuss First Quarter 2020 Financial Results
08:00pm, Wednesday, 22'nd Apr 2020
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, April 29, 2020 to discuss the company's first quarter 2020 financial resu
Why Alkermes (ALKS) Might Surprise This Earnings Season
12:49pm, Wednesday, 22'nd Apr 2020
Alkermes (ALKS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Alkermes (ALKS) Might Surprise This Earnings Season
12:49pm, Wednesday, 22'nd Apr 2020
Alkermes (ALKS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Back by Popular Demand: David Grossman's "8 Ways to Lead with Heart" Webinar Returning May 5th
12:31pm, Wednesday, 22'nd Apr 2020
8 Ways to Lead with Heart During Times of Uncertainty and Change, a complimentary 60-minute webinar for people leaders confronting the impacts of COVID-19, is returning in May. The webinar, led by Dav
Alkermes' candidate ALKS 4230 shows anti-tumor efficacy in publication ALKS
11:20am, Wednesday, 22'nd Apr 2020
Alkermes' candidate ALKS 4230 shows anti-tumor efficacy in publication ALKS
Alkermes Announces Publication of Preclinical Data for ALKS 4230 in the Journal for ImmunoTherapy of Cancer
11:00am, Wednesday, 22'nd Apr 2020
Alkermes plc (Nasdaq: ALKS) today announced the publication of preclinical data demonstrating the selectivity and anti-tumor efficacy of its investigational, immunotherapy candidate, ALKS 4230, in the
Why Alkermes (ALKS) Might Surprise This Earnings Season
12:00am, Wednesday, 22'nd Apr 2020Multiple Sclerosis Drugs Industry Assessment 2020: Immunomodulators, Immunosuppressants, Interferons and Others
02:45pm, Tuesday, 21'st Apr 2020
The "Multiple Sclerosis Drugs Market Global Report 2020" report has been added to ResearchAndMarkets.com's offering.
Nuveen Asset Management LLC Purchases 94,688 Shares of Alkermes Plc (NASDAQ:ALKS)
11:41am, Sunday, 19'th Apr 2020
Nuveen Asset Management LLC lifted its position in Alkermes Plc (NASDAQ:ALKS) by 25.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC
The "Multiple Sclerosis Drugs Market Global Report 2020" report has been added to ResearchAndMarkets.com's offering.
